Monokine Induced by Gamma Interferon (MIG)

Monokine Induced by Gamma Interferon (MIG; CXCL9) is a small cytokine belonging to the family of CXC chemokines. MIG is a T-cell chemoattractant whose expression is induced by interferon gamma. MIG production has proven to be a sensitive measure of antigen-specific IFN production. It affects the growth, movement, and activation state of cells that participate in immune and inflammatory response. MIG is chemotactic for activated T-cells and binds to CXCR3.

Swiss-Prot Accession Number: Q07325


Myriad RBM Publications Publications
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas (2023) Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Thomas F Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Elisabeth I Heath, John A Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson Journal for ImmunoTherapy of Cancer
Quantifying the spatial clustering characteristics of radiographic emphysema explains variability in pulmonary function (2023) Brian E. Vestal, Debashis Ghosh, Ra?l San Jos? Est?par, Katerina Kechris, Nature
Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na?ve schizophrenia (2022) Santiago G. Lago, Jakub Tomasik, Geertje F. Rees, Nitin Rustogi, Javier Vazquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Sabine Bahn Brain Behavior and Immunity
Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults (2022) Wivine Burny, Caroline Herve, Magalie Caubet, Juan Pablo Yazabal, Arnaud M Didierlaurent Vaccine
Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study (2022) Lars Krogvold, Angelo Genoni, Anna Puggioni, Daniela Campani, Sarah J. Richardson, Christine S. Flaxman, Bj?rn Edwin, Trond Buanes, Knut Dahl-J?rgensen & Antonio Toniolo Diabetologia
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab teserine in patients with small cell lung cancer (2021) Calvo E, Spira A, de Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburon L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B Cancer Treatment and Research Communities
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma (2021) Italiano A, Cassier PA, Lin CC, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V Cancer Immunology, Immunotherapy
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) Choueiri TK, Atkins MB, Rose TL, Alter RS, Yawen J, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF Investigational New Drugs
Identifying associations among genomic, proteomic and imaging biomarkers via adaptive sparse multi-view canonical correlation analysis (2021) Du L, Zhang J, Liu F, Wang H, Guo L, Han J, the Alzheimer's Disease Neuroimaging Initiative Medical Image Analysis
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma (2020) Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R American Journal of Hematology
Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181) (2020) Powderly J, Spira A, Kondo S, Doi T, Luke JL, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, Italiano A, Tosi D, Afar DE, Parikh A, Engelhardt B, Englert S, Lambert SL, Kasichayanula S, Mensing S, Menon R, Vosganian G, Tolcher A Clinical and Translational Science
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort (2018) Bhatt SP, Nath HP, Kim YI, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC, Bodduluri S, Han MK, Labaki WW, Michael Wells J, Martinez FJ, Barr RG, Dransfield MT, SPIROMICS investigators Respiratory Research
Serum thyroid-stimulating hormone and interleukin-8 levels in boys with autism spectrum disorder (2017) Singh S, Yazdani U, Gadad B, Zaman S, Hynan LS, Roatch N, Schutte C, Marti CN, Hewitson L and German DC J. Neuroinflammation
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research
Sj?gren?s Syndrome Patients with Ectopic Germinal Centers Present with a Distinct Salivary Proteome (2016) Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R Rheumatology
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. (2016) S?derlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Str?mberg U, Loskog A. Leuk Res
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. (2015) Christiansson L, Soderlund S, Mangsbo SM, Hjorth-Hansen H, H?glund M, Markevarn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Stromberg U. Mol Cancer Ther. 2015 Mar 11. pii: molcanther.0849.2014. [Epub ahead of print]
Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) Choueiri TK, Fishman MN, Escudier B, Stadler WM, Chasalow S, Ross-Macdonald P, Jure-Kunkel M, Sznol M, and Simon JS Cancer Res
Comparison of Plasma and Urine Biomarker Performance in Acute Kidney Injury (2015) Schley G, K?berle C, Manuilova E, Rutz S, Forster C, Weyand M, Formentini I, Kientsch-Engel R, Eckardt K-U, Willam C PLoS ONE
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) Berger T, Jacob C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T Journal of Neuroimmunology DOI: 10.1016/j.jneuroim.2014.10.001
Plasma biomarkers of depressive symptoms in older adults (2012) Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, Kim EJ, Wolk DA, Bennett DA, Chen-Plotkin A, Grossman M, Hu W, Lee VMY, Mackin RS, Trojanowski JQ, Wilson RS, Shaw LM Translational Psychiatry (2012) 2, e65;
Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer. (2009) Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Pri? D, B?chet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML J Urol 181: 1571-1580.